Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Easywell BiomedicalsROCO:1799 -5.43%55 Gross Margin % is 41.11% as of Dec. 2025, which is 44% above its 10-year median of 28.47. GuruFocus rates ROCO:1799 with a GF Score™ of 55/100 and a GF Value™ of NT$75.37 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 943 Drug Manufacturers companies, Easywell Biomedicals ranks worse than 53.23% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Easywell Biomedicals had a gross margin of 41.11% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Easywell Biomedicals Gross Margin % Related Terms
Easywell Biomedicals Gross Margin % Historical Data
* Premium members only.
The historical data trend for Easywell Biomedicals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Easywell Biomedicals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Easywell Biomedicals Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Easywell Biomedicals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Easywell Biomedicals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Easywell Biomedicals (ROCO:1799) has a Gross Margin % of 41.11% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Easywell Biomedicals and its competitors. This is 44% above median its historical median of 28.47. Over the past decade, Easywell Biomedicals' Gross Margin % has ranged from 5.08 to 62.85. According to the industry distribution chart, Easywell Biomedicals ranks #502 out of 943 companies in the Drug Manufacturers industry, placing it in the top 53.2%.
Is Easywell Biomedicals' Gross Margin % too high?
Easywell Biomedicals' current Gross Margin % of 41.11% is 44% above median its 10-year median of 28.47. Over the past 10 years, this metric has ranged from a low of 5.08 to a high of 62.85. The Drug Manufacturers industry median Gross Margin % is 48.54. Easywell Biomedicals' value of 41.11% is 15.3% below this industry median. Based on the distribution chart, Easywell Biomedicals ranks #502 out of 943 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Easywell Biomedicals has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Easywell Biomedicals' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Easywell Biomedicals ranks #502 out of 943 companies for Gross Margin %. This places Easywell Biomedicals in the lower half of its industry. The industry median Gross Margin % is 48.54. Easywell Biomedicals' value of 41.11% is 15.3% below this benchmark. Historically, Easywell Biomedicals' own Gross Margin % has ranged from 5.08 to 62.85 over the past decade. While the company's 10-year median is 28.47 vs. the industry median of 48.54, Easywell Biomedicals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Easywell Biomedicals's current Gross Margin % of 41.11% is 15.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Easywell Biomedicals and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Easywell Biomedicals's current Gross Margin % is 41.11%, which is 44% above median its own 10-year median of 28.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Easywell Biomedicals stock overvalued right now?
Based on GuruFocus' analysis, Easywell Biomedicals (ROCO:1799) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$75.37, compared to a current price of NT$32.25 — trading 57.2% below its estimated fair value. The current Gross Margin % is 41.11%, which is 44% above median its 10-year median of 28.47 and 15.3% below the Drug Manufacturers industry median of 48.54. Easywell Biomedicals' overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Easywell Biomedicals (ROCO:1799), the current Gross Margin % is 41.11% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Easywell Biomedicals (ROCO:1799) Overvalued in 2026?
Based on GuruFocus' analysis, Easywell Biomedicals stock appears to be undervalued.
The current stock price of NT$32.25 is trading 57.2% below its estimated GF Value™ of NT$75.37.
GuruFocus considers Easywell Biomedicals to be Significantly Undervalued.
Key valuation signals for ROCO:1799:
Gross Margin %: 41.11% (44% above median its 10-year median of 28.47)
GF Value™: NT$75.37 vs. price of NT$32.25 (57.2% below fair value)
Industry Position: 15.3% below the Drug Manufacturers median (#502 of 943)
No single metric tells the full story. See the ROCO:1799 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Easywell Biomedicals Inc is engaged in drug development, manufacturing, and sales of active pharmaceutical ingredients, generic drugs, and new drugs. It focuses on complex generics, new drug delivery platforms, and regenerative medicines, with cGMP. The company's segments include the Drug Development segment and the Other segment. Geographically, the company operates in America, China, and Taiwan regions.
55GF Score
Get the complete analysis for ROCO:1799
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1799 has been successfully added to your 
